Regeneron Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionPortside Wealth Group, LLC
Latest Disclosed Ownership1,978 shares
Latest Disclosed Value $ 1,528,290
Portside Wealth Group, LLC reports 10.75% increase in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On May 12, 2026 - Portside Wealth Group, LLC filed a 13F-HR form disclosing ownership of 1,978 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $1,528,290 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 21, 2026 disclosing 1,786 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of 10.75% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 1,978 192 10.75 1,528 10.89 0.1407
2026-01-21 2025-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 1,786 239 15.45 1,379 58.57 0.1854
2025-11-05 2025-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 1,547 225 17.02 870 25.22 0.1199
2025-08-11 2025-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 1,322 208 18.67 694 -1.70 0.1028
2025-04-14 2025-03-31 13F/A-1 REGENERON PHARMACEUTICALS COM 75886F107 1,114 338 43.56 707 27.90 0.1152
2025-04-10 2025-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 776 0 553 0.0828
2025-04-14 2024-12-31 13F/A-1 REGENERON PHARMACEUTICALS COM 75886F107 776 52 7.18 553 -27.46 0.0914
2025-01-15 2024-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 721 -3 758 0.1311
2024-10-31 2024-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 724 93 14.74 761 14.78 0.1300
2024-07-18 2024-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 631 32 5.34 663 15.10 0.1265
2024-04-17 2024-03-31 13F REGENERON PHARMACEUTICALS COM 75886F107 599 53 9.71 577 20.25 0.1067
2024-01-16 2023-12-31 13F REGENERON PHARMACEUTICALS COM 75886F107 546 58 11.89 480 19.45 0.0893
2023-10-27 2023-09-30 13F REGENERON PHARMACEUTICALS COM 75886F107 488 90 22.61 401 40.70 0.0754
2023-09-01 2023-06-30 13F/A-1 REGENERON PHARMACEUTICALS COM 75886F107 398 398 286 0.0531
2023-08-01 2023-06-30 13F REGENERON PHARMACEUTICALS COM 75886F107 17,114 17,114 12,297 0.0530
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.